MX2023001868A - Composicion de anticonceptivo oral de liberacion modificada. - Google Patents

Composicion de anticonceptivo oral de liberacion modificada.

Info

Publication number
MX2023001868A
MX2023001868A MX2023001868A MX2023001868A MX2023001868A MX 2023001868 A MX2023001868 A MX 2023001868A MX 2023001868 A MX2023001868 A MX 2023001868A MX 2023001868 A MX2023001868 A MX 2023001868A MX 2023001868 A MX2023001868 A MX 2023001868A
Authority
MX
Mexico
Prior art keywords
modified release
release oral
composition
oral contraceptive
medical
Prior art date
Application number
MX2023001868A
Other languages
English (en)
Spanish (es)
Inventor
Enrico Colli
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of MX2023001868A publication Critical patent/MX2023001868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
MX2023001868A 2020-08-14 2021-08-13 Composicion de anticonceptivo oral de liberacion modificada. MX2023001868A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382753.0A EP3954364A1 (en) 2020-08-14 2020-08-14 New modified release oral contraceptive composition
PCT/EP2021/072584 WO2022034209A1 (en) 2020-08-14 2021-08-13 New modified release oral contraceptive composition

Publications (1)

Publication Number Publication Date
MX2023001868A true MX2023001868A (es) 2023-05-09

Family

ID=72145348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001868A MX2023001868A (es) 2020-08-14 2021-08-13 Composicion de anticonceptivo oral de liberacion modificada.

Country Status (21)

Country Link
US (3) US12409141B2 (enExample)
EP (2) EP3954364A1 (enExample)
JP (1) JP2023538030A (enExample)
KR (1) KR20230067614A (enExample)
CN (1) CN116322701A (enExample)
AU (1) AU2021325372A1 (enExample)
BR (1) BR112023002654A2 (enExample)
CA (1) CA3191326A1 (enExample)
CL (1) CL2023000450A1 (enExample)
CO (1) CO2023002874A2 (enExample)
CR (1) CR20230127A (enExample)
DO (1) DOP2023000029A (enExample)
EC (1) ECSP23016038A (enExample)
IL (1) IL300578A (enExample)
JO (1) JOP20230032A1 (enExample)
MX (1) MX2023001868A (enExample)
PE (1) PE20231378A1 (enExample)
PY (1) PY2168235A (enExample)
UY (1) UY39379A (enExample)
WO (1) WO2022034209A1 (enExample)
ZA (1) ZA202303273B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260021110A1 (en) * 2024-07-18 2026-01-22 Chemo Research, S.L. Methods of oral contraception by controlled release of dienogest and ethynyl estradiol
WO2026146125A1 (en) 2024-12-30 2026-07-09 Chemo Research, S.L. Treatment of hirsutism, polycystic ovarian syndrome and other associated conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US7589082B2 (en) 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy
EP1690529A1 (de) 2005-02-15 2006-08-16 Schering AG Feste perorale Arzneiform zur Kontrazeption, die Dienogest und Ethinylestradiol enthält
DK1848406T3 (da) * 2005-02-15 2008-09-15 Jenapharm Gmbh Fast, penoral lægemiddelform til kontraception, der indeholder dienogest og ethynylestradiol
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system

Also Published As

Publication number Publication date
UY39379A (es) 2022-01-31
CO2023002874A2 (es) 2023-04-05
CR20230127A (es) 2023-06-23
CN116322701A (zh) 2023-06-23
US12409141B2 (en) 2025-09-09
DOP2023000029A (es) 2023-07-09
IL300578A (en) 2023-04-01
PE20231378A1 (es) 2023-09-07
US20260027058A1 (en) 2026-01-29
AU2021325372A1 (en) 2023-03-30
EP3954364A1 (en) 2022-02-16
US12409142B2 (en) 2025-09-09
CL2023000450A1 (es) 2023-10-20
WO2022034209A1 (en) 2022-02-17
JOP20230032A1 (ar) 2023-02-13
ECSP23016038A (es) 2023-04-28
EP4196098A1 (en) 2023-06-21
JP2023538030A (ja) 2023-09-06
US20240041775A1 (en) 2024-02-08
BR112023002654A2 (pt) 2023-04-04
ZA202303273B (en) 2026-02-25
PY2168235A (es) 2022-04-25
US20240350415A1 (en) 2024-10-24
CA3191326A1 (en) 2022-02-17
KR20230067614A (ko) 2023-05-16

Similar Documents

Publication Publication Date Title
BR112012014059A2 (pt) gel transdérmico de progestina / estradiol.
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
ZA202303273B (en) New modified release oral contraceptive composition
JP2013018787A5 (enExample)
JP2015187157A5 (enExample)
AU2012293593A8 (en) Use of estetrol as emergency contraceptive
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
DOP2006000223A (es) Procedimiento para la produccion de una preparacion farmacéutica monofasica para la terapia oral de la hemorragia uterina disfuncional.
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
JP2013047269A5 (enExample)
MX2023012801A (es) Nueva formulacion.
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
ATE395047T1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
NO20072687L (no) Farmasoytisk prevensjonspreparat
DK1937274T3 (da) Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception
UY29860A1 (es) Procedimiento para la producción de una preparación farmacéutica monofásica para la terapia oral de la hemorragia uterina disfuncional
MX2020011523A (es) Composicion farmaceutica adecuada para administracion vaginal en forma de ovulos y uso de la misma.
MX2024013108A (es) Composicion farmaceutica adecuada para administracion vaginal en forma de ovulos y uso de la misma
DK1910398T3 (da) 17-alfa-substituerede derivater af estradiol med sårhelende virkning
AR034810A1 (es) Composicion farmaceutica para la administracion por via nasal de estradiol y de noretisterona